

Florian Huemer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2004715/publications.pdf>

Version: 2024-02-01

31
papers

370
citations

933447

10
h-index

839539

18
g-index

32
all docs

32
docs citations

32
times ranked

678
citing authors

#	ARTICLE	IF	CITATIONS
1	Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. <i>BMC Cancer</i> , 2022, 22, 51.	2.6	3
2	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapyâ€”A Retrospective Bi-Centric Cohort Study. <i>Cancers</i> , 2022, 14, 93.	3.7	7
3	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	3.8	9
4	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. <i>Cancers</i> , 2021, 13, 650.	3.7	4
5	Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 906-909.	1.4	1
6	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburgâ€”a report from the AGMT COVID-19 Registry. <i>GeroScience</i> , 2021, 43, 1877-1897.	4.6	3
7	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 1466-1471.	1.1	6
8	Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1131-1136.	1.9	4
9	Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. <i>Lung Cancer</i> , 2021, 159, 84-95.	2.0	12
10	Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110421.	1.9	4
11	Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. <i>Cancers</i> , 2020, 12, 2812.	3.7	3
12	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2775.	2.4	10
13	Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1663.	2.4	7
14	Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancerâ€”Results from the AGMT GASTRIC-5 Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 935.	2.4	6
15	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	4.1	31
16	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. <i>Journal of Clinical Medicine</i> , 2019, 8, 1014.	2.4	41
17	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.	3.6	15
18	Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 159-166.e3.	2.3	14

#	ARTICLE	IF	CITATIONS
19	Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL2 and/or BIM. <i>European Journal of Haematology</i> , 2019, 102, 437-441.	2.2	18
20	C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1791.	2.4	9
21	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 115-125.	1.9	0
22	Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype. <i>World Neurosurgery</i> , 2018, 120, 442-447.	1.3	9
23	Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). <i>BMC Cancer</i> , 2018, 18, 11.	2.6	14
24	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16512-16520.	1.8	71
25	Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 141-144.	1.9	3
26	ASCO-update: gastrointestinal tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 240-243.	0.5	0
27	Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/ Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients – AGMT_GASTRIC-3. , 2017, 37, 5553-5558.		9
28	Immune checkpoint blockade in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 82-84.	0.5	17
29	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1501-1508.	4.9	28
30	Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. <i>BMC Cancer</i> , 2015, 15, 996.	2.6	8
31	Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer?. <i>Clinical Breast Cancer</i> , 2014, 14, e17-e20.	2.4	3